Mindfulness- and Acceptance-Based Interventions for Symptom Reduction in Individuals With Multiple Sclerosis: A Systematic Review and Meta-Analysis.
Study Goal
The researchers aimed to examine the effects of mindfulness- and acceptance-based interventions (MABIs) on reducing symptoms such as depression, anxiety, stress, fatigue, and pain in individuals with multiple sclerosis (MS).
Results Summary
Meta-analyses showed large effects of MABIs on reducing depressive symptoms, anxiety, stress, and pain immediately post-intervention, with moderate effects on fatigue. Large effects persisted for depressive symptoms, anxiety, and stress at follow-up, while fatigue showed moderate effects and pain showed no significant effect at follow-up.
Population
Individuals with multiple sclerosis (MS)
Effective Dosage
Not specified
Duration
Not specified
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
mindfulness- and acceptance-based interventions (MABIs) | decrease | depressive symptoms | individuals with multiple sclerosis (MS) | large effects | large effects of MABIs on reducing | #1 |
mindfulness- and acceptance-based interventions (MABIs) | decrease | anxiety | individuals with multiple sclerosis (MS) | large effects | large effects of MABIs on reducing | #2 |
mindfulness- and acceptance-based interventions (MABIs) | decrease | stress | individuals with multiple sclerosis (MS) | large effects | large effects of MABIs on reducing | #3 |
mindfulness- and acceptance-based interventions (MABIs) | decrease | pain | individuals with multiple sclerosis (MS) | large effects | large effects of MABIs on reducing | #4 |
mindfulness- and acceptance-based interventions (MABIs) | decrease | fatigue | individuals with multiple sclerosis (MS) | moderate effect | moderate effect of MABIs on reducing | #5 |
mindfulness- and acceptance-based interventions (MABIs) | decrease | depressive symptoms | individuals with multiple sclerosis (MS) | large effects | large effects of MABIs on reducing | #6 |
mindfulness- and acceptance-based interventions (MABIs) | decrease | anxiety | individuals with multiple sclerosis (MS) | large effects | large effects of MABIs on reducing | #7 |
mindfulness- and acceptance-based interventions (MABIs) | decrease | stress | individuals with multiple sclerosis (MS) | large effects | large effects of MABIs on reducing | #8 |
mindfulness- and acceptance-based interventions (MABIs) | decrease | fatigue | individuals with multiple sclerosis (MS) | moderate effect | moderate effect on reducing | #9 |
mindfulness- and acceptance-based interventions (MABIs) | no change | pain | individuals with multiple sclerosis (MS) | no significant effect | no significant effect of MABIs on reducing | #10 |
OBJECTIVE: To examine the effects of mindfulness- and acceptance-based interventions (MABIs) on reducing symptoms in individuals with multiple sclerosis (MS). DATA SOURCES: A comprehensive search was conducted within the PubMed, CINAHL, PsycINFO, and SCOPUS databases for articles published from inception to July 3, 2020. STUDY SELECTION: Randomized controlled trials (RCTs) were included if MABIs were provided to individuals with MS exclusively, with reported pre-and posttest results in symptoms of depression, anxiety, stress, fatigue, or pain. DATA EXTRACTION: Characteristics of the included RCTs and data for meta-analysis were extracted. The quality of the included RCTs was assessed using the Cochrane Collaboration risk of bias tool. DATA SYNTHESIS: A random effects model with the inverse variance method was used with effect size reported as standardized mean difference. Heterogeneity was assessed using the I RESULTS: Twenty-three RCTs met the eligibility criteria. Meta-analyses found large effects of MABIs on reducing depressive symptoms, anxiety, stress, and pain, as well as a moderate effect of MABIs on reducing fatigue at the immediate posttest. Large effects of MABIs on reducing depressive symptoms, anxiety, and stress at follow-up were also found, whereas a moderate effect on reducing fatigue was found at follow-up. There was no significant effect of MABIs on reducing pain at follow-up. CONCLUSIONS: Fewer studies were included in meta-analyses for pain at the immediate posttest and follow-up and stress and fatigue at follow-up. The overall risk of bias was unclear. Future high-quality studies with follow-up evaluations are needed to support effects of MABIs on reducing symptoms in individuals with MS and examine intervention features that increase and maintain effects.